Continuing Versus Switching Immunotherapy in Advanced Gastric Cancer

A single-center retrospective study of 169 patients with advanced gastric or gastroesophageal junction cancer who progressed after first-line immuno-chemotherapy. Guangxi Wang published this real-world data on figshare in June 2026, comparing survival outcomes for patients continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy.

Use Cases

• Compare progression-free survival (PFS) between treatment continuation and switch strategies based on the reported median PFS values.
• Analyze overall survival (OS) benefit for patients with specific biomarkers like PD-L1 expression ≥1%.
• Identify patient subgroups deriving greatest benefit from continued immunotherapy based on first-line therapy response and PFS duration.
• Assess the safety profile of continuing immune checkpoint inhibitors beyond progression compared to alternative regimens.

Strengths

• Includes data from 169 patients, providing a substantial real-world cohort.
• Reports specific survival metrics: median PFS of 4.4 vs. 3.0 months and median OS of 9.5 vs. 6.4 months.
• Analyses include multivariable adjustment and propensity score matching for robustness.
• Examines clinically relevant subgroups (e.g., PD-L1 expression, first-line response).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect single-center bias inherent to the study design.

Provenance

Source

figshare

Collection Method

Single-center retrospective study.

Freshness

Last updated 2026-06-03 04:51:12; freshness should be verified.